Marcus Shaker1, Matthew Greenhawt2. 1. From the Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 2. Section of Allergy and Immunology, Food Challenge and Research Unit, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
Background: Peanut allergy affects 1% to 4.5% of children, with the potential for severe reactions. The peanut allergy burden impacts families, communities, and societies. Objective: To provide an update on the peanut allergy burden of illness and diagnostic pitfalls. Methods: A narrative review of the literature that described the role of food allergy testing for the evaluation of clinical allergy or eczema, consequences of peanut allergy diagnosis, quality of life, and emerging peanut immunotherapies. Results: Peanut allergy is considered persistent in the majority of those diagnosed with it; however, fatal anaphylaxis is rare. There is an absence of evidence to support food allergy screening in children with eczema, apart from those with immediate food reactions. Allergist-directed education may enhance the quality of life for patients and families living with peanut allergy. Appropriate pricing, availability, and use of epinephrine autoinjectors may reduce peanut allergy burden of illness. Peanut oral immunotherapy may decrease anxiety but, on balance, may cause more episodes of peanut anaphylaxis than it prevents. Conclusion: The personal, family, community, and societal burden of peanut allergy is significant but can be reduced by preventing overdiagnosis. Patient education should be anchored in the appropriate risk perspective. Longer-term data are needed to better understand how peanut immunotherapy products can be leveraged to improve patients' quality of life.
Background: Peanutallergy affects 1% to 4.5% of children, with the potential for severe reactions. The peanutallergy burden impacts families, communities, and societies. Objective: To provide an update on the peanutallergy burden of illness and diagnostic pitfalls. Methods: A narrative review of the literature that described the role of food allergy testing for the evaluation of clinical allergy or eczema, consequences of peanutallergy diagnosis, quality of life, and emerging peanut immunotherapies. Results:Peanutallergy is considered persistent in the majority of those diagnosed with it; however, fatal anaphylaxis is rare. There is an absence of evidence to support food allergy screening in children with eczema, apart from those with immediate food reactions. Allergist-directed education may enhance the quality of life for patients and families living with peanutallergy. Appropriate pricing, availability, and use of epinephrine autoinjectors may reduce peanutallergy burden of illness. Peanut oral immunotherapy may decrease anxiety but, on balance, may cause more episodes of peanut anaphylaxis than it prevents. Conclusion: The personal, family, community, and societal burden of peanutallergy is significant but can be reduced by preventing overdiagnosis. Patient education should be anchored in the appropriate risk perspective. Longer-term data are needed to better understand how peanut immunotherapy products can be leveraged to improve patients' quality of life.
Authors: Katy Gallop; Sarah Acaster; Jane de Vries; Richard Browne; Robert Ryan; Sarah Baker; George Du Toit Journal: Patient Prefer Adherence Date: 2022-05-20 Impact factor: 2.314
Authors: Vibha Sharma; Jennifer Jobrack; Wendy Cerenzia; Stephen Tilles; Robert Ryan; Regina Sih-Meynier; Stefan Zeitler; Michael Manning Journal: PLoS One Date: 2020-12-03 Impact factor: 3.240
Authors: Marcus S Shaker; John Oppenheimer; Mitchell Grayson; David Stukus; Nicholas Hartog; Elena W Y Hsieh; Nicholas Rider; Cullen M Dutmer; Timothy K Vander Leek; Harold Kim; Edmond S Chan; Doug Mack; Anne K Ellis; David Lang; Jay Lieberman; David Fleischer; David B K Golden; Dana Wallace; Jay Portnoy; Giselle Mosnaim; Matthew Greenhawt Journal: J Allergy Clin Immunol Pract Date: 2020-03-26